{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:50:42Z","timestamp":1793746242093,"version":"4.6.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Dengue virus (DENV), as a widely circulating arbovirus, is prone to causing dengue fever and poses a serious threat to human health. Nevertheless, there is currently no ideal safe and effective vaccine for DENV. In particular, vaccination with approved DENV vaccines may increase the chance of infection with heterotypic serotypes of DENV and the risk of severe dengue upon infection. Antibody-dependent enhancement (ADE) is considered a major mechanism contributing to severe disease in secondary infections, which seriously restricts the safety and efficacy of the vaccine. Notably, many studies have shown that DENV T cell epitopes induce cellular immunity by producing large amounts of cytokines, which may contribute to controlling DENV infection and potentially modulating ADE risk. However, the relationship between T cell responses and ADE is complex and requires careful balance to avoid immunopathology. Additionally, the novel mRNA-LNP vaccine has shown promise in preclinical models due to its superior stability and controllability. This review highlights the potential of T cell epitope-based vaccines to complement existing strategies of DENV vaccine development and provide new ideas for the prevention and treatment of DENV.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1785887","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:43:28Z","timestamp":1775022208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Research progress of dengue virus T cell epitope mediated cellular immunity in avoiding ADE"],"prefix":"10.3389","volume":"17","author":[{"given":"Mengye","family":"Ma","sequence":"first","affiliation":[{"name":"Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]},{"name":"School of Basic Medical Sciences, Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated People\u2019s Hospital of Ningbo University","place":["Ningbo, Zhejiang, China"]},{"name":"Institute of Hematology, Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieting","family":"Pan","sequence":"additional","affiliation":[{"name":"Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]},{"name":"School of Basic Medical Sciences, Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Yunnan Provincial Key Laboratory of Public Health and Biosafety, Yunnan Center for Disease Control and Prevention (Yunnan Provincial Academy of Preventive Medical Sciences)","place":["Kunming, China"]},{"name":"Health Laboratories Center, Yunnan Center for Disease Control and Prevention (Yunnan Provincial Academy of Preventive Medical Sciences)","place":["Kunming, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilei","family":"Yan","sequence":"additional","affiliation":[{"name":"Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]},{"name":"School of Basic Medical Sciences, Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqing","family":"Xu","sequence":"additional","affiliation":[{"name":"Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]},{"name":"School of Basic Medical Sciences, Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Ding","sequence":"additional","affiliation":[{"name":"Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]},{"name":"School of Basic Medical Sciences, Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]},{"name":"School of Basic Medical Sciences, Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00705-023-05833-3","article-title":"Correction to: Molecular evolution of dengue virus: a Bayesian approach using 1581 whole-genome sequences from January 1944 to July 2022","volume":"168","author":"Wolf","year":"2023","journal-title":"Arch Virol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1899057","article-title":"Viral evolution sustains a dengue outbreak of enhanced severity","volume":"10","author":"Inizan","year":"2021","journal-title":"Emerging Microbes Infect"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-013-1645-3","article-title":"Secondary infection as a risk factor for dengue hemorrhagic fever\/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection","volume":"158","author":"Guzman","year":"2013","journal-title":"Arch Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.572681","article-title":"Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine","volume":"10","author":"Shukla","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.179771","article-title":"Frequency of dengue virus-specific T cells is related to infection outcome in endemic settings","volume":"10","author":"G\u00e1lvez","year":"2025","journal-title":"JCI Insight"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.07.036","article-title":"Development of a novel ZIKV vaccine comprised of immunodominant CD4+ and CD8+ T cell epitopes identified through comprehensive epitope mapping in Zika virus infected mice","volume":"39","author":"Sun","year":"2021","journal-title":"Vaccine"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401597","article-title":"CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice","volume":"193","author":"Zellweger","year":"2014","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.virs.2022.07.003","article-title":"A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice","volume":"37","author":"He","year":"2022","journal-title":"Virol Sin"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice","volume":"18","author":"Zhang","year":"2020","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jaut.2017.04.008","article-title":"Original antigenic sin: a comprehensive review","volume":"83","author":"Vatti","year":"2017","journal-title":"J Autoimmun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00531-z","article-title":"Dengue vaccines: an update","volume":"36","author":"Torres-Flores","year":"2022","journal-title":"BioDrugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1949983","article-title":"Dengue vaccine: an update","volume":"19","author":"Huang","year":"2021","journal-title":"Expert Rev Anti-infect Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/25151355211015839","article-title":"Dengvaxia: the world\u2019s first vaccine for prevention of secondary dengue","volume":"9","author":"Tully","year":"2021","journal-title":"Ther Adv Vaccines Immunother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2254964","article-title":"An open-label, phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life","volume":"19","author":"Patel","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD\u2122 vaccine","volume":"15","author":"Whitehead","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac418","article-title":"Clinical safety experience of TAK-003 for dengue fever: a new tetravalent live attenuated vaccine candidate","volume":"76","author":"Patel","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination","volume":"225","author":"L\u00f3pez-Medina","year":"2022","journal-title":"J Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw068","article-title":"Dengue vaccine: the need, the challenges, and progress","volume":"214","author":"Rothman","year":"2016","journal-title":"J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.19-0461","article-title":"Safety and immunogenicity of different formulations of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico: final results after 3 years of follow-up from a randomized, placebo-controlled phase I study","volume":"102","author":"Diaz","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.10.017","article-title":"T cell and memory B cell responses in tetravalent DNA, tetravalent inactivated and tetravalent live-attenuated prime-boost dengue vaccines in rhesus macaques","volume":"39","author":"Sun","year":"2021","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a phase I randomized clinical trial in flavivirus-na\u00efve adults","volume":"15","author":"Manoff","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1261770","article-title":"Vaccines licensed and in clinical trials for the prevention of dengue","volume":"13","author":"Torresi","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-0410-5_17","article-title":"Tetravalent DNA vaccine product as a vaccine candidate against dengue","volume":"1143","author":"Porter","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.10.085","article-title":"Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine","volume":"30","author":"Porter","year":"2012","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(00)00105-5","article-title":"A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys","volume":"18","author":"Kochel","year":"2000","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02482-20","article-title":"A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02724-07","article-title":"A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus","volume":"82","author":"Raviprakash","year":"2008","journal-title":"J Virol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.198069","article-title":"Comparative analysis of adenovirus, mRNA, and protein vaccines reveals context-dependent immunogenicity and efficacy","volume":"10","author":"Awakoaiye","year":"2025","journal-title":"JCI Insight"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104922","article-title":"Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study","volume":"99","author":"Miauton","year":"2024","journal-title":"EBioMedicine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50437-3","article-title":"Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B\/NS3 and blocks replication organelle formation","volume":"15","author":"Kiemel","year":"2024","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006209","article-title":"Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein","volume":"12","author":"Budigi","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234236","article-title":"Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America","volume":"15","author":"Carpp","year":"2020","journal-title":"PLoS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial","volume":"29","author":"Beckett","year":"2011","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.01.013","article-title":"Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences","volume":"30","author":"Sankaradoss","year":"2022","journal-title":"Mol Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/jhg.2008.5","article-title":"The HLA genomic loci map: expression, interaction, diversity and disease","volume":"54","author":"Shiina","year":"2009","journal-title":"J Hum Genet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nri3014","article-title":"Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms","volume":"11","author":"Rothman","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000304","article-title":"Protective and enhancing HLA alleles, HLA-DRB1*0901 and HLA-A*24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome","volume":"2","author":"Nguyen","year":"2008","journal-title":"PloS NeglTrop Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2002.600405.x","article-title":"HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais","volume":"60","author":"Stephens","year":"2002","journal-title":"Tissue Antigens"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1115-8_18","article-title":"Customized predictions of peptide-MHC binding and T-cell epitopes using EPIMHC","volume":"1184","author":"Molero-Abraham","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0198-8859(01)00298-1","article-title":"Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations","volume":"62","author":"Cao","year":"2001","journal-title":"Hum Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101725","article-title":"Viral T-cell epitopes \u2013 identification, characterization and clinical application","volume":"66","author":"Schroeder","year":"2023","journal-title":"Semin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-082119-124838","article-title":"T cell epitope predictions","volume":"38","author":"Peters","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.13.171","article-title":"Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections","volume":"9","author":"Mathew","year":"2014","journal-title":"Future Microbiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02675-12","article-title":"Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection","volume":"87","author":"Rivino","year":"2013","journal-title":"J Virol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01108-14","article-title":"Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection","volume":"88","author":"Weiskopf","year":"2014","journal-title":"J Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.980210","article-title":"Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals","volume":"10","author":"Comber","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nm887","article-title":"Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever","volume":"9","author":"Mongkolsapaya","year":"2003","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0625-1","article-title":"Immune-mediated cytokine storm and its role in severe dengue","volume":"39","author":"Srikiatkhachorn","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7030074","article-title":"Impact of HIV-1 diversity on its sensitivity to neutralization","volume":"7","author":"Stefic","year":"2019","journal-title":"Vaccines"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj5365","article-title":"Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination","volume":"7","author":"Caniels","year":"2021","journal-title":"Sci Adv"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0801974","article-title":"A protective role for dengue virus-specific CD8+ T cells","volume":"182","author":"Yauch","year":"2009","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-323-82763-8.00184-9","article-title":"Dengue","volume":"370","author":"Halstead","year":"2007","journal-title":"Lancet (London England)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.virusres.2014.10.022","article-title":"Identification of conserved and HLA-A*2402-restricted epitopes in dengue virus serotype 2","volume":"196","author":"Duan","year":"2015","journal-title":"Virus Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.03.002","article-title":"Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses","volume":"29","author":"Li","year":"2011","journal-title":"Vaccine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24167","article-title":"Identification of cytotoxic T lymphocyte epitopes in dengue virus serotype 1","volume":"87","author":"Duan","year":"2015","journal-title":"J Med Virol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2010.07.014","article-title":"Immunogenicity of novel dengue virus epitopes identified by bioinformatic analysis","volume":"153","author":"S\u00e1nchez-Burgos","year":"2010","journal-title":"Virus Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100278","article-title":"Immune cell phenotypes associated with disease severity and long-term neutralizing antibody titers after natural dengue virus infection","volume":"2","author":"Rouers","year":"2021","journal-title":"Cell Rep Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1160\/th09-03-0208","article-title":"Plasma leakage in dengue haemorrhagic fever","volume":"102","author":"Srikiatkhachorn","year":"2009","journal-title":"Thromb Haemostasis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/v14112575","article-title":"Immune-mediated pathogenesis in dengue virus infection","volume":"14","author":"Khanam","year":"2022","journal-title":"Viruses"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh3067","article-title":"Insights into dengue immunity from vaccine trials","volume":"15","author":"Ooi","year":"2023","journal-title":"Sci Transl Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02125","article-title":"Human T cell response to dengue virus infection","volume":"10","author":"Tian","year":"2019","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2010.07.004","article-title":"Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization","volume":"38","author":"Ch\u00e1vez","year":"2010","journal-title":"Biologicals"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-8-361","article-title":"Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines","volume":"8","author":"Bui","year":"2007","journal-title":"BMC Bioinf"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz1029","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jim.2010.11.009","article-title":"MULTIPRED2: a computational system for large-scale identification of peptides predicted to bind to HLA supertypes and alleles","volume":"374","author":"Zhang","year":"2011","journal-title":"J Immunol Methods"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01424","article-title":"A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice","volume":"10","author":"Roth","year":"2019","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-immunol-042617-053142","article-title":"Immune response to dengue and Zika","volume":"36","author":"Ngono","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001742","article-title":"Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans","volume":"6","author":"Lindow","year":"2012","journal-title":"PloS NeglTrop Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/v16050730","article-title":"Regional variation of the CD4 and CD8 T cell epitopes conserved in circulating dengue viruses and shared with potential vaccine candidates","volume":"16","author":"Chawla","year":"2024","journal-title":"Viruses"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02482-20","article-title":"A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J Virol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.26633\/rpsp.2023.34","article-title":"Dengue, chikungunya, and Zika virus infections in Latin America and the Caribbean: a systematic review","volume":"47","author":"Santos","year":"2023","journal-title":"Rev Panamericana Salud Publ = Pan Am J Public Health"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2007.10.012","article-title":"Computational prediction and identification of dengue virus-specific CD4(+) T-cell epitopes","volume":"132","author":"Wen","year":"2008","journal-title":"Virus Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1785887\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:43:29Z","timestamp":1775022209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1785887\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":75,"alternative-id":["10.3389\/fimmu.2026.1785887"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1785887","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1785887"}}